BioSpace News Archive

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen’s 44th Annual Health Care Conference.

BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2023, and introduces 2024 revenue guidance.

Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:SYRE), a biotechnology company advancing a pipeline of investigational antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (“IBD”), today announced its fourth quarter and full year 2023 financial results and provided program and corporate updates.

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a review of recent accomplishments and anticipated upcoming developments.

PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2023.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, reported its fourth-quarter 2023 financial results.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2023.

Precision BioSciences, Inc. announced the commencement of a proposed underwritten public offering of its common stock and accompanying warrants to purchase shares of common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers.

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.